30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Seikagaku Quarterly Revenue -

Seikagaku posted 2QFY16 revenue of ¥6.8BB (~US $68.3MM), -1.4% vs. the prior year. (Period ended 9/30/16)

  • Revenue results impacted by yen appreciation and price reductions in Japan, offset by higher U.S. sales of Gel-One
  • U.S. SUPARTZ FX sales fell against market competition for multiple-injection products
  • China ARTZ sales continued to fall due to governmental price pressure, yen appreciation and other factors
  • Ferring Pharmaceuticals acquired exclusive development and commercialization rights to SI-6603 injectable condoliase, indicated to treat lumbar disc herniation
  • Seikagaku still seeks to obtain Japan approval for SI-6603, though it will likely not occur during its current fiscal year
  • Entered into an exclusive U.S. distribution agreement with Zimmer Biomet for VISCO-3 HA-based viscosupplement to treat knee OA pain

Sources: Seikagaku Corporation; ORTHOWORLD Inc.


This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.